Red Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration
Advanced Science · 2023
DOI: 10.1002/advs.202301985 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Shuting Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, Laboratory of Molecul…. Hauptthemen laut MEDLINE: Porphyrins, Photochemotherapy, Macular Degeneration, Choroidal Neovascularization. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Choroidal neovascularization (CNV) is the key pathological event of wet age‐related macular degeneration (wAMD) leading to irreversible vision loss. Currently, anti‐angiogenic therapy with anti‐vascular endothelial growth factor (VEGF) agents has become the standard treatment for wAMD, while it is still subject to several limitations, including the safety concerns of monthly intravitreal administration and insufficient efficacy for neovascular occlusion. Combined therapy with photodynamic therapy (PDT) and anti‐angiogenic agents has emerged as a novel treatment paradigm. Herein, a novel and less‐invasive approach is reported to achieve anti‐angiogenic and photodynamic combination therapy of wAMD by intravenous administration of a photoactivatable nanosystem (Di‐DAS‐VER NPs). The nanosystem is self‐assembled by reactive oxygen species (ROS)‐sensitive dasatinib (DAS) prodrug and photosensitizer verteporfin (VER). After red‐light irradiation to the diseased eyes, intraocular release of anti‐angiogenic DAS is observed, together with selective neo‐vessels occlusion by VER‐generated ROS. Notably, Di‐DAS‐VER NPs demonstrates promising therapeutic efficacy against CNV with minimized systemic toxicity. The study enables an efficient intravenous wAMD therapy by integrating a photoactivation process with combinational therapeutics into one simple nanosystem.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The U…
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-sen University, Guangzhou, 510060, China.
- Department of Ophthalmology, Vancouver General Hospital, Vancouver, BC, V5Z 0A6, Canada.
ORCID-Profile: Weiping Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, S., Cui, K., Long, K., Li, J., Fan, N., Lam, W. C., Liang, X., & Wang, W. (2023). Red Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration. Advanced Science. https://doi.org/10.1002/advs.202301985
Vancouver
Xu S, Cui K, Long K, Li J, Fan N, Lam WC, et al. Red Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration. Advanced Science. 2023. doi:10.1002/advs.202301985
BibTeX
@article{Xu2023,
author = {Xu, Shuting and Cui, Kaixuan and Long, Kaiqi and Li, Jia and Fan, Ni and Lam, Wai-Ching and Liang, Xiaoling and Wang, Weiping},
title = {Red Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202301985}
}
EUVIMED